-
1
-
-
0023120533
-
Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial
-
Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. New Engl J Med 1987, 316:73-78.
-
(1987)
New Engl J Med
, vol.316
, pp. 73-78
-
-
Eschbach, J.W.1
Egrie, J.C.2
Downing, M.R.3
Browne, J.K.4
Adamson, J.W.5
-
2
-
-
0024790160
-
Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter trial
-
Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter trial. Ann Intern Med 1989, 111:992-1000.
-
(1989)
Ann Intern Med
, vol.111
, pp. 992-1000
-
-
Eschbach, J.W.1
Abdulhadi, M.H.2
Browne, J.K.3
-
3
-
-
0032572913
-
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
-
Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson R, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New Engl J Med 1998, 339:584-590.
-
(1998)
New Engl J Med
, vol.339
, pp. 584-590
-
-
Besarab, A.1
Bolton, W.K.2
Browne, J.K.3
Egrie, J.C.4
Nissenson, R.5
Okamoto, D.M.6
-
4
-
-
33646345152
-
NKF-K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease
-
National Kidney Foundation NKF-K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006, 47(3):S1-146.
-
(2006)
Am J Kidney Dis
, vol.47
, Issue.3
-
-
National Kidney Foundation1
-
5
-
-
84882909419
-
-
National Kidney Foundation. NKF-K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for American Chronic Kidney Disease. 2007 Update on Hemoglobin Target
-
National Kidney Foundation. NKF-K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for American Chronic Kidney Disease. 2007 Update on Hemoglobin Target. Am J Kidney Dis, 2007, in press.
-
Am J Kidney Dis, 2007, in press
-
-
-
6
-
-
0034765367
-
Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%
-
Collins AJ, Li S, St.Peter W, Ebben J, Roberts T, Ma JZ, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001, 12:2465-2473.
-
(2001)
J Am Soc Nephrol
, vol.12
, pp. 2465-2473
-
-
Collins, A.J.1
Li, S.2
St.Peter, W.3
Ebben, J.4
Roberts, T.5
Ma, J.Z.6
-
7
-
-
0033052842
-
Hematocrit level and associated mortality in hemodialysis patients
-
Ma JZ, Ebben J, Xia H, Collins AJ Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999, 10:610-619.
-
(1999)
J Am Soc Nephrol
, vol.10
, pp. 610-619
-
-
Ma, J.Z.1
Ebben, J.2
Xia, H.3
Collins, A.J.4
-
8
-
-
0037075272
-
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin
-
Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002, 346:469-475.
-
(2002)
N Engl J Med
, vol.346
, pp. 469-475
-
-
Casadevall, N.1
Nataf, J.2
Viron, B.3
-
9
-
-
9644283016
-
Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysi of randomized controlled trials
-
Strippoli GFM, Craig JC, Manno C, Schena FP Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysi of randomized controlled trials. J Am Soc Nephrol 2004, 15:3154-3165.
-
(2004)
J Am Soc Nephrol
, vol.15
, pp. 3154-3165
-
-
Strippoli, G.F.M.1
Craig, J.C.2
Manno, C.3
Schena, F.P.4
-
10
-
-
29244456140
-
Evidence-based systematic literature review of the literature of hemoglobin/hematocrit and all-cause mortality in dialysis patients
-
Volkova N, Arab L Evidence-based systematic literature review of the literature of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis 2006, 47:24-26.
-
(2006)
Am J Kidney Dis
, vol.47
, pp. 24-26
-
-
Volkova, N.1
Arab, L.2
-
11
-
-
84882832206
-
-
These two articles are the first reported results in dialysis patients of the use of recombinant human erythropoietin. The results are important in terms of how this transformed anemia management in patients on dialysis and subsequently with anemia due to other conditions.
-
-
-
-
12
-
-
84882832968
-
-
This article describes what remains as the largest clinical trial prospectively studying the clinical outcomes resulting from low versus normal hematocrit/hemoglobin levels in dialysis patients. There was a trend toward a higher combined mortality and first nonfatal myocardial infarction in the higher hematocrit group, leading to the early termination of the study.
-
-
-
-
13
-
-
84882883915
-
-
These two articles are the most recent revisions to the NKF-K/DOQI clinical practice guidelines and recommendations for adults and children with anemia and CKD.
-
-
-
-
14
-
-
84882851852
-
-
This article reviews two observational studies that examined the association between hematocrit and outcomes in hemodialysis patients using Medicare/HCFA databases that support the clinical practice of maintaining hemoglobin levels in the range of 11 to 12 g/dL.
-
-
-
-
15
-
-
84882856804
-
-
This is the original description of pure red cell aplasia due to antierythropoietin antibodies.
-
-
-
-
16
-
-
84882914245
-
-
This article reviews the available studies concerning the outcomes associated with hemoglobin levels in hemodialysis patients.
-
-
-
|